Dr Reddy's Labs shares surge 10% to hit record high

Global brokerage firm Credit Suisse is of the view that Revlimid generic cashflows should be significant (over $700 million)

Shares of Dr Reddy's Laboratories surged almost 10 percent to hit their fresh record high of Rs 5,302.85 on BSE on September 18.

Shares of the company vaulted after the company said it had settled patent litigation with US-based Bristol-Myers Squibb's unit, Celgene, over cancer treatment Revlimid.

"In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Dr Reddy's Labs with a license to sell volume-limited amounts of generic lenalidomide capsules in the US beginning on a confidential date after March 2022," said a regulatory filing by the company on September 17.

On September 16, the company said it had launched an over-the-counter (OTC) eye allergy drop Olopatadine Hydrochloride Ophthalmic Solution in the US market.

Global brokerage firm Credit Suisse is of the view that Revlimid generic cashflows should be significant (over $700 million).

The brokerage firm has an 'outperform' rating on the stock and raised the target price to Rs 5,750 from Rs 5,100.

As per CNBC-TV18, Credit Suisse believes Dr. Reddy's is one of the two players that can market Avigan in the US for COVID treatment. Besides, the company can increase share in Suboxone with innovator guiding for lower volume.

Global financial firm Citi has a buy recommendation on the stock with a target price of Rs 5,000.

Citi highlighted that the company can now launch a generic version of Revlimid in the US after March 2022 and will get a licence to sell an agreed-upon percentage of volume till January 2026.

"This is the third settlement for gRevlimid after those of Natco and Alvogen and we assume the company will be able to launch Revlimid generic in September 2022," Citi said.

SD Solutions advises users to check with certified experts before taking any investment decisions.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

SD Solutions

Search This Blog